Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
10:20am, Monday, 29'th Aug 2022 Zacks Investment Research
Style Box ETF report for SPGP
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why
05:34pm, Friday, 26'th Aug 2022 Zacks Investment Research
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
5 Top Stocks Cathie Wood Is Selling This Week
04:53pm, Friday, 26'th Aug 2022
Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail inve
Regeneron Announces Investor Conference Presentations
04:05pm, Thursday, 25'th Aug 2022
TARRYTOWN, N.Y. , Aug. 25, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2022 Wells Fargo Healthcare Conference at 11:00 a.m.
Regeneron: There Are Challenges But Growth To Resume In 2023
11:48am, Thursday, 25'th Aug 2022
Regeneron will report a decline in revenues this year due to the lack of COVID-19 antibody sales. Growth is set to resume in 2023, driven primarily by Dupixent.
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
11:58am, Wednesday, 24'th Aug 2022 The Motley Fool
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
7 Cathie Wood Stocks to Buy on the Dip
02:00pm, Monday, 22'nd Aug 2022
Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
04:32pm, Friday, 19'th Aug 2022 Zacks Investment Research
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down
04:32pm, Wednesday, 17'th Aug 2022 Zacks Investment Research
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
Wall Street Breakfast: China The Outlier
10:57am, Monday, 15'th Aug 2022 Seeking Alpha
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
2 Top Biotech Stocks to Buy Right Now
10:50am, Friday, 12'th Aug 2022 The Motley Fool
Both of these companies are leading players in the pharmaceutical industry.
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus
02:57pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular di
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
05:25am, Sunday, 07'th Aug 2022 Seeking Alpha
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.
If You Invested $10,000 in Regeneron Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today
01:30pm, Saturday, 06'th Aug 2022 The Motley Fool
Has the healthcare stock been a better investment than the S&P 500?
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
05:43pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
